420 related articles for article (PubMed ID: 10877836)
1. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.
Di Marzo V; Hill MP; Bisogno T; Crossman AR; Brotchie JM
FASEB J; 2000 Jul; 14(10):1432-8. PubMed ID: 10877836
[TBL] [Abstract][Full Text] [Related]
2. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.
Maneuf YP; Crossman AR; Brotchie JM
Exp Neurol; 1997 Nov; 148(1):265-70. PubMed ID: 9398468
[TBL] [Abstract][Full Text] [Related]
3. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum.
Giuffrida A; Parsons LH; Kerr TM; Rodríguez de Fonseca F; Navarro M; Piomelli D
Nat Neurosci; 1999 Apr; 2(4):358-63. PubMed ID: 10204543
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus.
Venderova K; Brown TM; Brotchie JM
Exp Neurol; 2005 Jul; 194(1):284-7. PubMed ID: 15899265
[TBL] [Abstract][Full Text] [Related]
5. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
Ferrer B; Asbrock N; Kathuria S; Piomelli D; Giuffrida A
Eur J Neurosci; 2003 Sep; 18(6):1607-14. PubMed ID: 14511339
[TBL] [Abstract][Full Text] [Related]
6. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM
FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity.
Patel S; Rademacher DJ; Hillard CJ
J Pharmacol Exp Ther; 2003 Sep; 306(3):880-8. PubMed ID: 12808005
[TBL] [Abstract][Full Text] [Related]
8. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
[TBL] [Abstract][Full Text] [Related]
9. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
10. Activation of brain-type cannabinoid receptors interferes with preimplantation mouse embryo development.
Yang ZM; Paria BC; Dey SK
Biol Reprod; 1996 Oct; 55(4):756-61. PubMed ID: 8879486
[TBL] [Abstract][Full Text] [Related]
11. Effects of intrapallidal cannabinoids on rotational behavior in rats: interactions with the dopaminergic system.
Sañudo-Peña MC; Walker JM
Synapse; 1998 Jan; 28(1):27-32. PubMed ID: 9414015
[TBL] [Abstract][Full Text] [Related]
12. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors.
Martín AB; Fernandez-Espejo E; Ferrer B; Gorriti MA; Bilbao A; Navarro M; Rodriguez de Fonseca F; Moratalla R
Neuropsychopharmacology; 2008 Jun; 33(7):1667-79. PubMed ID: 17957223
[TBL] [Abstract][Full Text] [Related]
13. Effects on turning of microinjections into basal ganglia of D(1) and D(2) dopamine receptors agonists and the cannabinoid CB(1) antagonist SR141716A in a rat Parkinson's model.
El-Banoua F; Caraballo I; Flores JA; Galan-Rodriguez B; Fernandez-Espejo E
Neurobiol Dis; 2004 Jul; 16(2):377-85. PubMed ID: 15193294
[TBL] [Abstract][Full Text] [Related]
14. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.
Gómez R; Navarro M; Ferrer B; Trigo JM; Bilbao A; Del Arco I; Cippitelli A; Nava F; Piomelli D; Rodríguez de Fonseca F
J Neurosci; 2002 Nov; 22(21):9612-7. PubMed ID: 12417686
[TBL] [Abstract][Full Text] [Related]
15. Regulation of subthalamic neuron activity by endocannabinoids.
Morera-Herreras T; Ruiz-Ortega JA; Taupignon A; Baufreton J; Manuel I; Rodriguez-Puertas R; Ugedo L
Synapse; 2010 Sep; 64(9):682-98. PubMed ID: 20336631
[TBL] [Abstract][Full Text] [Related]
16. Exogenous anandamide protects rat brain against acute neuronal injury in vivo.
van der Stelt M; Veldhuis WB; van Haaften GW; Fezza F; Bisogno T; Bar PR; Veldink GA; Vliegenthart JF; Di Marzo V; Nicolay K
J Neurosci; 2001 Nov; 21(22):8765-71. PubMed ID: 11698588
[TBL] [Abstract][Full Text] [Related]
17. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.
Gubellini P; Picconi B; Bari M; Battista N; Calabresi P; Centonze D; Bernardi G; Finazzi-Agrò A; Maccarrone M
J Neurosci; 2002 Aug; 22(16):6900-7. PubMed ID: 12177188
[TBL] [Abstract][Full Text] [Related]
18. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.
Silverdale MA; McGuire S; McInnes A; Crossman AR; Brotchie JM
Exp Neurol; 2001 Jun; 169(2):400-6. PubMed ID: 11358453
[TBL] [Abstract][Full Text] [Related]
19. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.
Sugiura T; Kondo S; Kishimoto S; Miyashita T; Nakane S; Kodaka T; Suhara Y; Takayama H; Waku K
J Biol Chem; 2000 Jan; 275(1):605-12. PubMed ID: 10617657
[TBL] [Abstract][Full Text] [Related]
20. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
